key: cord-0790020-i1e0we2d
authors: Fan, Moli; Qiu, Wei; Bu, Bitao; Xu, Yan; Yang, Huan; Huang, Dehui; Lau, Alexander Y.; Guo, Jun; Zhang, Mei-Ni; Zhang, Xinghu; Yang, Chun-Sheng; Chen, Jingshan; Zheng, Pei; Liu, Qiang; Zhang, Chao; Shi, Fu-Dong
title: Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders
date: 2020-06-04
journal: Neurol Neuroimmunol Neuroinflamm
DOI: 10.1212/nxi.0000000000000787
sha: 1c3a805f2af2ea3afee0f51004059871d71a1b08
doc_id: 790020
cord_uid: i1e0we2d

OBJECTIVE: Disease-modifying drugs (DMDs) may alter the immune status and thus increase the susceptibility to coronavirus disease 2019 (COVID-19) in patients with MS or neuromyelitis optica spectrum disorders (NMOSD). However, evidence supporting this notion is currently lacking. In this study, we conducted a survey on the risk of COVID-19 in patients with MS and NMOSD. METHODS: The survey was conducted through the Chinese Medical Network for Neuroinflammation. Patients in 10 MS centers from 8 cities including Wuhan were included. Information about MS and NMOSD disease duration and the usage of DMDs were collected. Data of suspected cases of COVID-19 were obtained from hospital visits, questionnaires, and patient self-reporting. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was confirmed through clinical evaluation by a panel of experts in conjunction with chest CT and viral RNA detection. RESULTS: Eight hundred eighty-two of 1,804 (48.89%) patients with MS and 2,129 of 3,060 (69.58%) patients with NMOSD were receiving DMDs. There were no alterations in the patients' DMD regimen during January 15, 2020, to March 15, 2020, the 3-month period. None of the patients with MS treated with DMDs had COVID-19. However, 2 patients with relapsing NMOSD were diagnosed with COVID-19-related pneumonia. After treatment, both patients recovered from pneumonia and neither patient experienced new attacks due to predisposing SARS-CoV-2 infection in the following 2 months. CONCLUSIONS: No increased risk of COVID-19 infection was observed in patients with MS or NMOSD, irrespective of whether these patients received DMDs. A battery of stringent preventive measures adopted by neurologists to reduce COVID-19 infection in these patients may have contributed to low risk of COVID-19 infection.

The number of the novel coronavirus disease 2019 (COVID-19) cases and mortality grow rapidly around the world. Aged individuals with preexisting medical conditions are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with disease and mortality occurring predominantly in this group. [1] [2] [3] It is thus conceivable that patients with MS or neuromyelitis optica spectrum disorders (NMOSDs) who are receiving disease-modifying treatments have increased susceptibility to COVID-19 infection and disease. However, evidence supporting this notion is currently lacking.

We have conducted a survey through the Chinese Medical Network for Neuroinflammation (CMNN). The CMNN consists of neurologists specialized in managing patients with MS and NMOSD from 47 hospitals across China (figure 1). MS and NMOSD were diagnosed according to the 2017 McDonald criteria and 2015 International Panel for Neuromyelitis Optica Diagnosis criteria, respectively. All patients with MS and NMOSD managed in 10 centers from 8 cities including Wuhan were enrolled in this study. Information about disease duration and usage of disease-modifying drugs (DMDs) were collected. Data of suspected cases of COVID-19 were obtained from hospital visits, online questionnaires (supplementary file, links.lww.com/NXI/A266), and patient self-reporting via emails or phone calls. Patients who did not respond to questionnaires were excluded from this study. Confirmation of SARS-CoV-2 infection was determined through clinical evaluation by a panel of experts in conjunction with a set of tests including chest CT and viral RNA detection by real-time fluorescent PCR from nasopharyngeal swab samples.

All data are published in this article.

We conducted a survey for COVID-19 infection during January 15 to March 15. One thousand eight hundred four of 1,836 (98.26%) patients with MS and 3,060 of 3,128 (97.82%) patients with NMOSD from 10 MS/NMOSD centers across China, including Tongji Hospital from Wuhan, have responded (figure 2). The mean disease duration was 4.64 years for patients with MS and 4.94 years for patients with NMOSD. For MS, 882 (48.89%) patients were receiving DMDs, and the remaining patients received non-DMDs such as corticosteroids, traditional Chinese medicines, or other drugs. For NMOSD, 2,129 (69.58%) patients were receiving DMDs. There were no alterations in the patients' DMD regimen during this 3-month period (table, figures 3 and 4). None of the patients with MS treated with DMDs were diagnosed with COVID-19. However, 2 patients with relapsing NMOSD, a 53-year-old man from Wuhan and a 49-year-old man from Beijing, were diagnosed with COVID-19-related pneumonia, and SARS-CoV-2 infection was confirmed by viral RNA detection. Both patients had received oral methylprednisolone as maintenance therapy to prevent relapses, and neither had been treated with other DMDs after diagnosis. After treatment according to the Chinese protocols for COVID-19, 4 both patients recovered from pneumonia and neither patient experienced new attacks due to predisposing SARS-CoV-2 infection in the following 2 months. Neurologists from centers who have not contributed to these data have reported no COVID-19infected patients with MS or NMOSD diagnosed in their clinic.

Natalizumab, rituximab, and fingolimod usage is associated with reactivation of John Cunningham virus and progressive multifocal leukoencephalopathy in patients with MS. 5 Side effects for newer therapies such as eculizumab, inebilizumab, satralizumab, and tocilizumab in NMOSD are unclear, partly because of the relatively short duration and small numbers of patients' exposure to these medications. Because these DMDs interfere with multiple arms of the immune system, altered immune functions in these patients are expected. Despite this anticipated risk, we did not observe an escalated rate of COVID-19 infection, even at the epicenter of the outbreak in Wuhan. SARS-CoV-2 has spread to all the provinces of China from the Wuhan epicenter since January 2020. The overall incidence of COVID-19 infection in China is estimated at 6/10 5 subjects comparable with the estimated incidence of NMOSD in China. These results from China are consistent with observations in some MS centers from Korea, Japan, and Singapore where no COVID-19 cases have been reported for patients with MS or NMOSD treated with DMDs (personal communications). As with the general public, patients with MS and NMOSD do not have immunity to SARS-CoV-2, and altered immunity induced by DMDs in patients with MS or NMOSD, if any, appears insufficient to enhance the susceptibility to infection. 6 and its spread is still intensifying in many parts of the world, a full-scale preparedness plan, with unconditional support for manpower and resources from federal and local governments, is required to better manage neurologic patients during the pandemic. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Comorbidities and multi-organ injuries in the treatment of COVID-19

Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies

A novel coronavirus outbreak of global health concern

This study was supported by the Advanced Innovation Center for Human Brain Protection (Neuroimmune 01), and the National Science Foundation of China (91642205, 81830038, and 81601019).

The authors report no disclosures relevant to the manuscript. None of the funding organizations were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Go to Neurology.org/NN for full disclosures.Publication history